NCT02530489 2026-02-17
Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
Clinical Trials
158 trialsNCT02999477 2026-01-29
A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT04524702 2026-01-23
Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer
Emory University
Phase 2 Completed
NCT03910387 2025-12-16
Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer
Emory University
Phase 2 Completed
NCT03177291 2025-12-05
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02514681 2025-09-10
PRECIOUS
Japan Breast Cancer Research Group
Phase 3 Completed
NCT02905578 2025-08-27
A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)
University of Iowa
Phase 2 Completed
NCT03579771 2025-08-15
Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer
Emory University
Phase 2 Completed
NCT02769832 2025-07-29
Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer
University of Iowa
Phase 2 Completed
NCT02030860 2025-07-25
A Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT02723331 2025-07-01
Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates
University of Colorado, Denver
Phase 2 Completed
NCT04548440 2025-06-12
Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients
Sun Yat-sen University
Phase 2 Completed
NCT04821765 2025-05-30
Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Completed
NCT05516589 2025-05-22
neoCHANCE-2
West China Hospital
Phase 2 Completed
NCT03554044 2025-05-21
T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer
University of California, San Francisco
Phase 1 Completed
NCT03107182 2025-05-06
OPTIMA-II
University of Chicago
Phase 2 Completed
NCT04581343 2025-05-04
PanCAN-SR1
Pancreatic Cancer Action Network
Phase 1 Completed
NCT01818063 2025-04-30
Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer
Thomas Jefferson University
Phase 2 Completed
NCT04247165 2025-03-12
LAPTOP
Herlev Hospital
Phase 1/2 Completed
NCT01220154 2025-02-21
Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT00583349 2025-02-17
Intravesicular Abraxane for Treatment-Refractory Bladder Cancer
Columbia University
Phase 1/2 Completed
NCT03240016 2025-01-16
ABLE
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT03535727 2024-12-31
A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT02573493 2024-12-27
APA
Washington University School of Medicine
Phase 2 Completed
NCT03246074 2024-10-24
Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT03507491 2024-10-04
Nab-paclitaxel in Combination with Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors
Emory University
Phase 1 Completed
NCT02258659 2024-09-24
OPTIMA
University of Chicago
Phase 2 Completed
NCT01847326 2024-07-31
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer
University of Chicago
Phase 1 Completed
NCT02020707 2024-07-26
Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers
Mayo Clinic
Phase 1 Completed
NCT02024009 2024-07-25
SCALOP-2
University of Oxford
Phase 1/2 Completed
NCT01822314 2024-03-07
ETNA
Fondazione Michelangelo
Phase 3 Completed
NCT03283761 2024-02-06
FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma
Big Ten Cancer Research Consortium
Phase 2 Completed
NCT02607202 2024-01-26
AGNOSTOS
Fondazione del Piemonte per l'Oncologia
Phase 2 Completed
NCT03415854 2023-12-15
NABPLAGEMD
HonorHealth Research Institute
Phase 2 Completed
NCT02716038 2023-12-12
Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC
Columbia University
Phase 2 Completed
NCT02178436 2023-11-07
Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer
Barbara Ann Karmanos Cancer Institute
Phase 1/2 Completed
NCT03304210 2023-11-07
PIPAC-nabpac
University Hospital, Ghent
Phase 1 Completed
NCT03121352 2023-10-06
Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT02767557 2023-09-22
PACTO
Herlev Hospital
Phase 2 Completed
NCT02427841 2023-09-06
Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
OHSU Knight Cancer Institute
Phase 2 Completed
NCT01470417 2023-08-22
GAIN-1
University of Florida
Phase 2 Completed
NCT03003546 2023-06-15
Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial
Mayo Clinic
Phase 1 Completed
NCT03345810 2023-06-15
DURATION
AIO-Studien-gGmbH
Phase 2 Completed
NCT02333188 2023-05-31
Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
University of Chicago
Phase 1 Completed
NCT02620865 2023-05-15
BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer
Barbara Ann Karmanos Cancer Institute
Phase 1/2 Completed
NCT03112590 2023-04-19
Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT01036087 2023-03-30
Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01565499 2023-03-30
Neoadjuvant Treatment With Nab-paclitaxel for Patients With Stage II and III Luminal Breast Cancer
Spanish Breast Cancer Research Group
Phase 2 Completed
NCT02930902 2023-02-09
Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01446016 2023-01-23
CAT
The Methodist Hospital Research Institute
Phase 2 Completed